

Author Relationships With Industry and Other Entities (Comprehensive)—2019 ACC Health Policy Statement on Cardiologist Compensation and Opportunity Equity

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Pamela S. Douglas <i>(Chair)</i>	Duke University Medical Center in Cardiovascular Diseases—Ursula Geller Professor of Research	<ul style="list-style-type: none"> • Bay Labs • CardioDX • Elsevier • Genome Magazine (s) • Pappas Ventures • UpToDate (s) 	None	<ul style="list-style-type: none"> • CardioDX 	<ul style="list-style-type: none"> • 23andMe (n) • Abbott (n) • Akros (n) • City of Hope (n) • Contrafact (n) • Defense Threat Reduction Agency (n) • Department of Defense /Defense Advanced Research Agency (n) • HeartFlow (n) • Kowa (n) • MSKCC (n) • NIH (n) • Partners HealthCare (n) • Singulex (n) • MedImmune, TIMI 63B REAL (DSMB) • U.S Air Force (n) • Verily Life Sciences (n) 	<ul style="list-style-type: none"> • Dr Footprint (n) • Exploragen (n) • Fabric Genomics • Host Response (n) • Origin Commercial Advisors (n) • David H. Murdock Research Institute (n) • Patient Advocate Foundation (n) 	None
Cathleen Biga	Cardiovascular Management of Illinois—President; Chief Executive Officer	<ul style="list-style-type: none"> • Cardiology Advocacy Alliance (s) 	<ul style="list-style-type: none"> • Medaxion Advisory Board (n) 	<ul style="list-style-type: none"> • Aftershock (s) • Cardiovascular Management of Illinois (s) 	None	<ul style="list-style-type: none"> • American Association of Cardiovascular and Pulmonary Rehabilitation (n) 	None
Kristin M. Burns	NHLBI/NIH—Medical Officer, Division of Cardiovascular Sciences	None	None	None	None	None	None
Richard A. Chazal	Lee Health—Medical Director, Heart and Vascular Institute	None	None	None	None	<ul style="list-style-type: none"> • Lee Health (s) 	None

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Michael Cuffe	HCA Healthcare—Vice President, Medical Affairs	None	None	None	None	• HCA Healthcare (s)	None
James M. Daniel, Jr.	Hancock, Daniel and Johnson, P.C.—Director	None	None	None	None	None	None
Catherine Garzio	Stanford University—Vice Chair and Director of Finance and Administration	None	None	None	None	None	None
Robert Harrington	Stanford University—Professor and Chair, Department of Medicine	<ul style="list-style-type: none"> • Adverse Events (n) • Vida Health (n) • WebMD (s) 	None	• Element Science (n)	<ul style="list-style-type: none"> • Apple • AstraZeneca (DSMB) (s) • Bristol Myers Squibb (s) • CSL Behring (s) • Janssen Research and Development (DSMB) (s) • MyoKardia • Novartis (s) • Portola (s) • Sanofi-Aventis (s) 	<ul style="list-style-type: none"> • American Heart Association (n) • College of the Holy Cross (n) • Scanadu • SignalPath (Evidint) (s) • Stanford Health Care (n) 	None
Hena N. Patel	Rush University Medical Center—Cardiology Fellow	None	None	None	None	None	None
Mary Norine Walsh	St Vincent Heart Center—Medical Director, Heart Failure and Cardiac Transplantation	None	None	None	None	<ul style="list-style-type: none"> • PCORI • Thoratec‡ 	None
Michael J. Wolk	Weill Medical College of Cornell University—Clinical Professor of Medicine, Weill Medical College of Cornell University; New York Cardiology Associates	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the

purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinicaldocuments/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

(s) Significant relationship.

(n) No financial benefit.

‡ Relationship with this company is limited to enrolling patients in clinical trials. This disclosure was entered under the Clinical Trial Enroller category in the ACC's disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the ACC/AHA Disclosure Policy for Writing Committees.

DSMB=Data Safety Monitoring Board; NIH=National Institutes of Health; NHLBI=National Heart, Lung and Blood Institute; PCORI=Patient-Centered Outcomes Research Institute.